Zobrazeno 1 - 5
of 5
pro vyhledávání: '"V A Keyan"'
Publikováno v:
Терапевтический архив, Vol 88, Iss 2, Pp 49-57 (2016)
Aim. To assess the diagnostic accuracy of the controlled attenuation parameter (CAP) to determine the grade of hepatic steatosis (HS) in patients with chronic liver diseases (CLD) of different etiologies and to compare the obtained results with morph
Externí odkaz:
https://doaj.org/article/51395aec2ee2486e8d44aed9e4939410
Autor:
A. V. Anisonyan, Yu. G. Sandler, T. Yu. Khaimenova, V. A. Keyan, K. G. Saliev, E. S. Sbikina, E. V. Vinnitskaya
Publikováno v:
Терапевтический архив, Vol 92, Iss 8, Pp 73-78 (2020)
Aim. To evaluate the frequency of liver fibrosis progression to stage 34 among patients with non-alcoholic fatty liver disease (NAFLD), type 2 diabetes and obesity, to identify predictors of severe liver fibrosis, to propose an algorithm for diagnosi
Externí odkaz:
https://doaj.org/article/afe3f23eedf3465e86b3f486e34a8e64
Autor:
E. V. Vinnitskaya, Yu. G. Sandler, V. A. Keyan, T. Yu. Khaymenova, E. A. Orlova, A. V. Polukhina, L. N. Gendrikson
Publikováno v:
Alʹmanah Kliničeskoj Mediciny, Vol 45, Iss 5, Pp 366-376 (2017)
Pruritus can be a prominent symptom in patients with chronic liver disorders, especially those with cholestasis, and substantially affects quality of life. Management of pruritus in cholestatic liver diseases remains a complicated medical problem. Th
Externí odkaz:
https://doaj.org/article/27f61073acdb4445b541c840ff4ff0bc
Autor:
K. G. Saliev, V A Keyan, E V Vinnitskaya, T Y Khaimenova, E. S. Sbikina, Yu G Sandler, A V Anisonyan
Publikováno v:
Терапевтический архив, Vol 92, Iss 8, Pp 73-78 (2020)
To evaluate the frequency of liver fibrosis progression to stage 34 among patients with non-alcoholic fatty liver disease (NAFLD), type 2 diabetes and obesity, to identify predictors of severe liver fibrosis, to propose an algorithm for diagnosing fi
Publikováno v:
Терапевтический архив, Vol 88, Iss 2, Pp 49-57 (2016)
To assess the diagnostic accuracy of the controlled attenuation parameter (CAP) to determine the grade of hepatic steatosis (HS) in patients with chronic liver diseases (CLD) of different etiologies and to compare the obtained results with morphologi